tradingkey.logo
๎™

BridgeBio Oncology Therapeutics Ord Shs

BBOT
12.180USD
-0.340-2.72%
์ข…๊ฐ€ย 12/22, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
286.34M์‹œ๊ฐ€์ด์•ก
60.33P/E TTM
๎™

BridgeBio Oncology Therapeutics Ord Shs

12.180
-0.340-2.72%

์ž์„ธํ•œ ๋‚ด์šฉ์€ ํšŒ์‚ฌ

BridgeBio Oncology Therapeutics Ord Shs ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ - -
ํšŒ์‚ฌ ์ด๋ฆ„- -
์ƒ์žฅ์ผ- -
CEO- -
์ง์› ์ˆ˜- -
์œ ํ˜•- -
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒ- -
์ฃผ์†Œ- -
๋„์‹œ- -
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†Œ- -
๊ตญ๊ฐ€- -
์šฐํŽธ ๋ฒˆํ˜ธ- -
์ „ํ™”- -
์›น์‚ฌ์ดํŠธ- -
์ข…๋ชฉ ์ฝ”๋“œ - -
์ƒ์žฅ์ผ- -
CEO- -

BridgeBio Oncology Therapeutics Ord Shs์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
,
,
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
,
,
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Dec 10
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Dec 10
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Cormorant Asset Management, LP
22.35%
BridgeBio Pharma, Inc.
18.24%
Deerfield Management Company, L.P.
6.11%
BC Global Opportunities IX LP
5.46%
Omega Fund Management, LLC
4.11%
๊ธฐํƒ€
43.73%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Cormorant Asset Management, LP
22.35%
BridgeBio Pharma, Inc.
18.24%
Deerfield Management Company, L.P.
6.11%
BC Global Opportunities IX LP
5.46%
Omega Fund Management, LLC
4.11%
๊ธฐํƒ€
43.73%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Hedge Fund
41.69%
Corporation
26.98%
Investment Advisor/Hedge Fund
10.78%
Venture Capital
10.12%
Investment Advisor
5.17%
Research Firm
0.26%
Individual Investor
0.11%
๊ธฐํƒ€
4.88%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 9
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 9
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
73
54.44M
68.05%
+15.73M
2025Q3
72
54.42M
68.03%
+15.72M
2025Q2
49
16.72M
87.47%
-855.66K
2025Q1
43
16.79M
88.78%
-267.82K
2024Q4
41
16.75M
88.56%
+227.86K
2024Q3
36
16.37M
86.59%
-5.42K
2024Q2
33
16.38M
89.02%
+311.06K
2024Q1
31
16.07M
84.98%
+7.80M

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Cormorant Asset Management, LP
17.88M
22.35%
--
--
Sep 30, 2025
BridgeBio Pharma, Inc.
13.81M
17.43%
+13.81M
--
Aug 29, 2025
Deerfield Management Company, L.P.
4.89M
6.11%
--
--
Sep 30, 2025
BC Global Opportunities IX LP
4.37M
5.46%
+3.27M
+296.89%
Sep 04, 2025
Omega Fund Management, LLC
3.29M
4.11%
+3.29M
--
Sep 30, 2025
Wellington Management Company, LLP
2.96M
3.7%
+2.78M
+1504.24%
Sep 30, 2025
Alphabet, Inc.
2.82M
3.53%
+2.82M
--
Sep 30, 2025
EcoR1 Capital, LLC
2.82M
3.53%
+2.82M
--
Sep 30, 2025
Enavate Sciences GP, LLC
2.63M
3.28%
+2.63M
--
Sep 30, 2025
Citadel Advisors LLC
2.54M
3.17%
+1.11M
+77.84%
Sep 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 9
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 9
์ด๋ฆ„
๋น„์œจ
Tema Oncology ETF
0.26%
Schwab U.S. Small-Cap ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Health Innovation Active ETF
0%
Tema Oncology ETF
๋น„์œจ0.26%
Schwab U.S. Small-Cap ETF
๋น„์œจ0.01%
Schwab U.S. Broad Market ETF
๋น„์œจ0%
iShares Health Innovation Active ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

BridgeBio Oncology Therapeutics Ord Shs์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
BridgeBio Oncology Therapeutics Ord Shs์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Cormorant Asset Management, LP๋Š” 17.88M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 22.35%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
BridgeBio Pharma, Inc.๋Š” 13.81M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 17.43%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Deerfield Management Company, L.P.๋Š” 4.89M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 6.11%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
BC Global Opportunities IX LP๋Š” 4.37M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 5.46%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Omega Fund Management, LLC๋Š” 3.29M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 4.11%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

BridgeBio Oncology Therapeutics Ord Shs์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
BridgeBio Oncology Therapeutics Ord Shs์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
Cormorant Asset Management, LP
BridgeBio Pharma, Inc.
Deerfield Management Company, L.P.์ž…๋‹ˆ๋‹ค.

BridgeBio Oncology Therapeutics Ord Shs(BBOT)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q4 ๊ธฐ์ค€์œผ๋กœ, BridgeBio Oncology Therapeutics Ord Shs์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 73๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 54.44M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 68.05%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q3 ๋Œ€๋น„ 0.02% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

BridgeBio Oncology Therapeutics Ord Shs์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
-- ๊ธฐ์ค€, BridgeBio Oncology Therapeutics Ord Shs์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™